Novartis AG’s gene therapy Luxturna for blindness is recommended for use on England’s public health service, according to the country’s healthcare cost-effectiveness watchdog NICE.
Future of Healthcare
Algorithms, Apps, Artificial Intelligence, August 2019, Blindness, Business, Diabetes, Diabetic Macular Edema, Digital therapeutics, Health Outcomes, Healthcare, Issue Archives, Marketing & Advertising, Medical Devices, Prediabetes, Smart assistants, Smart Phones, U.S. Centers for Disease Control and Prevention, Virtual RealityI got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.
ProQR Therapeutics N.V. announced that the company received Fast Track designation from the Food and Drug Administration for QR-421a for Usher syndrome type 2.
Johnson & Johnson Vision, a broad-based global leader in eye health, launched a worldwide campaign to #spotlightsight in honor of World Sight Day on October 11, 2018.
“Shark Week,” the insanely popular week-long festival of flesh-ripping, terror-inducing finned creatures, is in full-swing on the Discovery Channel and no doubt will be just as popular as ever in […]